BIOMAT Database Logo BIOMAT Database Logo

In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models. 1988

Z Zylicz, and D J Wagener, and H van Rennes, and E van der Kleijn, and P Lelieveld, and L A van den Broek, and H C Ottenheijm
Dept. of Internal Medicine, St. Radboud University Hospital, Nijmegen, The Netherlands.

Sparsomycin (Sm) is a known inhibitor of ribosomal protein synthesis with an attractive anticancer potential. Recently, several analogues of Sm which are more active than the parent drug were selected for further study on the basis of in vitro investigations. Six analogues as well as the parent drug were tested for their antitumor activity in eight in vivo murine tumor models: P388 and L1210 leukemias, RC renal cell carcinoma, B16 melanoma, C38 colon carcinoma, LL Lewis lung carcinoma, C22LR osteosarcoma and M5076 sarcoma. Sm itself appeared to have only borderline activity on L1210 leukemia. The analogues that were most active in vitro showed also the highest in vivo activity. The most sensitive tumors were RC, L1210 and P388. Minimal activity was found on B16 and no activity on C22LR, M5076, C38 and LL. The most active compounds are deshydroxy-Sm, ethyl-deshydroxy-Sm and n-pentyl-Sm. There was a considerable loss of activity when L1210 leukemia was implanted sc while the drugs were administered iv. Only one drug, ethyl-deshydroxy-Sm appeared to be active in this assay. No single most effective compound could be found in this study. The overall activity of Sm and its analogues is moderate. The three analogues which show high activity in three ascitic tumors will be further investigated using human tumor xenograft models.

UI MeSH Term Description Entries
D007928 Lethal Dose 50 The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population. LD50,Dose 50, Lethal
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D007941 Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene. P388D(1) Leukemia,P388, Leukemia
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Z Zylicz, and D J Wagener, and H van Rennes, and E van der Kleijn, and P Lelieveld, and L A van den Broek, and H C Ottenheijm
Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
January 2004, Anticancer research,
Z Zylicz, and D J Wagener, and H van Rennes, and E van der Kleijn, and P Lelieveld, and L A van den Broek, and H C Ottenheijm
Antitumor activity of IFN-lambda in murine tumor models.
June 2006, Journal of immunology (Baltimore, Md. : 1950),
Z Zylicz, and D J Wagener, and H van Rennes, and E van der Kleijn, and P Lelieveld, and L A van den Broek, and H C Ottenheijm
Structure-activity relationships of sparsomycin and its analogues. Octylsparsomycin: the first analogue more active than sparsomycin.
March 1984, Journal of medicinal chemistry,
Z Zylicz, and D J Wagener, and H van Rennes, and E van der Kleijn, and P Lelieveld, and L A van den Broek, and H C Ottenheijm
Pyrimidinylpropenamides as antitumor agents. Analogues of the antibiotic sparsomycin.
March 1977, Journal of medicinal chemistry,
Z Zylicz, and D J Wagener, and H van Rennes, and E van der Kleijn, and P Lelieveld, and L A van den Broek, and H C Ottenheijm
Evaluation of antitumor activity of Bordetella pertussis in two murine tumor models.
July 1975, Journal of the National Cancer Institute,
Z Zylicz, and D J Wagener, and H van Rennes, and E van der Kleijn, and P Lelieveld, and L A van den Broek, and H C Ottenheijm
In vitro and in vivo anticancer activity of mitozolomide and sparsomycin in human tumor xenografts, murine tumors and human bone marrow.
January 1990, Journal of cancer research and clinical oncology,
Z Zylicz, and D J Wagener, and H van Rennes, and E van der Kleijn, and P Lelieveld, and L A van den Broek, and H C Ottenheijm
[The in vivo antitumor activity of murine liver tumor vaccine expressing MIP-1alpha].
October 2002, Zhonghua wai ke za zhi [Chinese journal of surgery],
Z Zylicz, and D J Wagener, and H van Rennes, and E van der Kleijn, and P Lelieveld, and L A van den Broek, and H C Ottenheijm
Sparsomycin analogs. VI. Synthesis and antitumor activity of octylsparsomycin analogs.
March 1989, Chemical & pharmaceutical bulletin,
Z Zylicz, and D J Wagener, and H van Rennes, and E van der Kleijn, and P Lelieveld, and L A van den Broek, and H C Ottenheijm
Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models.
January 1985, Cancer research,
Z Zylicz, and D J Wagener, and H van Rennes, and E van der Kleijn, and P Lelieveld, and L A van den Broek, and H C Ottenheijm
Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
September 1986, Journal of medicinal chemistry,
Copied contents to your clipboard!